ClinicalTrials.gg
CompletedNCT03331315POPUpdated Dec 7, 2023Results posted

Toradol v. Celecoxib for Postoperative Pain

A Phase 2 interventional study of Celecoxib and Ketorolac in Pain, Postoperative, sponsored by Michael Ulm, MD. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-07.

Sponsored by Michael Ulm, MD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Sep 2013, registered Apr 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing celecoxib in Pain, Postoperative — 2 open to participants now, 2 under way, none of them phase 3. Celecoxib · Pain, Postoperative.

Enrollment
8th of 19
170 · median 132
Started
2013
the only one that year
Phase 2
5 of 19
none open now
Registered
7th of 19
by date

Among the 19 studies testing celecoxib in Pain, Postoperative, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 5 in phase 2, and was the 7th registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 19 studies testing celecoxib in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing celecoxib in Pain, Postoperative, or all of them as a file.
02

Study summary

Randomized control trial between ketorolac versus celecoxib for postoperative pain following hysterectomy.

Read the detailed description

Purpose:

To determine if Celebrex (Celecoxib) is as effective as Toradol (Ketorolac) at controlling postoperative pain when given in addition to standard postoperative pain control regimens.

Rationale:

Toradol (Ketorolac) is currently used by many surgeons as adjuvant therapy in addition to standard narcotics in managing immediate postoperative pain. Toradol (Ketorolac) is a non-steroidal anti-inflammatory drug that acts as a non-selective cyclooxygenase (COX), inhibiting COX-1 and COX-2 isoforms. (Toradol) Ketorolac has been associated with significant complications including postoperative bleeding and acute renal insufficiency. Celebrex (Celecoxib) is a selective COX-2 inhibitor that has been associated with adverse cardiovascular outcomes in patients with pre-existing cardiac disease but not with postoperative bleeding or renal insufficiency. Celebrex (Celecoxib) has also been shown to control postoperative pain but has never been compared to Toradol (Ketorolac).

Population:

Patients undergoing hysterectomy on the gynecology oncology service.

Design:

Randomized control trial.

Procedures:

All patients will receive a standard postoperative pain regimen with oral Tylenol (Acetaminophen), oral Lortab (Hydrocodone/Acetaminophen) as needed, and IV Dilaudid (Hydromorphone) as needed.

Randomization: Each participant will be assigned a number using a random number generator for assignment to one of the two postoperative pain regimens:

Arm 1:

Patients ages 18-65 will receive IV Toradol (Ketorolac) 30mg q6 hrs after their operation for 48 hrs or until hospital discharge if patients are discharged home in less than 48 hours after their operation.

**Patients over age 65 will receive IV Toradol (Ketorolac) 15mg q6hrs instead of 30mg

Arm 2:

Patients who will receive oral Celebrex (Celecoxib) 400mg 1 hour prior to their procedure then 200mg oral twice daily for a total of seven days. Patients discharged prior to 7 days will be given a prescription for Celebrex (Celecoxib) to complete a total of 7 days.

Following surgery all patients will be given a postoperative questionnaire at the day of surgery, which was returned at the two week postoperative visit, examining time until return to ADLs, days of narcotic use, and number of narcotic pills used.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing hysterectomy

Exclusion criteria

Exclusion Criteria:

  • Coronary Artery Disease
  • Peptic Ulcer Disease
  • Chronic Renal Disease
  • Liver disease
  • Alcohol Abuse
  • Daily narcotic usage
  • Narcotic use 24 hours prior to surgery
  • Crohn's Disease
  • History of myocardial infarction
  • History of stroke
  • Preoperative hematocrit less than 24
  • Asthma
  • Ulcerative Colitis
  • Diverticulitis
  • Aspirin Allergy
  • Sulfonamide Allergy
  • Pre-operative pain score of greater than 3
  • Patients undergoing procedures that may involve bowel resection or bowel reanastomosis.
  • Allergy to any non-steroidal anti-inflammatory drug
  • Cardiac anomaly or disease
  • Congestive Heart Failure
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Active comparator
    Ketorolac

    Patients receiving scheduled ketorolac postoperatively

    Drug: Ketorolac

  • Experimental
    Celecoxib

    Patients receiving celebrex preoperative and postoperatively for 7 days

    Drug: Celecoxib

Interventions

06

What researchers measure

Primary outcomes

  1. Average Inpatient Postoperative Pain Score

    Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff.

    Time frame: 48 hrs following surgery

Secondary outcomes

  1. Average Inpatient Hydromorphone Use

    Average inpatient hydromorphone use measured in milligrams

    Time frame: 48 hrs following surgery

  2. Average Inpatient Ondansetron Use

    Average inpatient ondansetron use measured in milligrams

    Time frame: 48 hrs following surgery

  3. Total Hospital Stay

    Total hospital stay from time fo admission to time of discharge measured in hours

    Time frame: Following surgery

  4. Number of Participants With Perioperative Complications

    Perioperative Complications measured intraoperatively and postoperatively by type

    Time frame: During and after surgery

  5. Return to Activities of Daily Living

    Average number of days required for complete return to independent activities of daily living

    Time frame: 2 weeks after discharge

  6. Days of Oral Narcotic Use After Discharge

    Measured using postoperative questionnaire

    Time frame: 2 weeks after discharge

  7. Number of Oral Narcotic Pills Used After Discharge

    Number of oral narcotic pills used after discharge until 2 week postoperative visit.

    Time frame: 2 weeks after discharge

07

Results

Posted Jun 4, 2018

Participant flow

Participant flow — Overall Study
MilestoneKetorolacCelecoxib
Started8882
Completed7068
Not completed1814
Withdrew: Physician decision1814

Outcome measures

PrimaryAverage Inpatient Postoperative Pain Score

Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff.

Time frame:
48 hrs following surgery
Reported as:
Mean · units on a scale
Average Inpatient Postoperative Pain Score
units on a scaleKetorolacCelecoxib
Average Inpatient Postoperative Pain Score2.7 ± 1.92.4 ± 1.6
SecondaryAverage Inpatient Hydromorphone Use

Average inpatient hydromorphone use measured in milligrams

Time frame:
48 hrs following surgery
Reported as:
Mean · Milligrams
Average Inpatient Hydromorphone Use
MilligramsKetorolacCelecoxib
Average Inpatient Hydromorphone Use0.7 ± 1.00.8 ± 1.0
SecondaryAverage Inpatient Ondansetron Use

Average inpatient ondansetron use measured in milligrams

Time frame:
48 hrs following surgery
Reported as:
Mean · Milligrams
Average Inpatient Ondansetron Use
MilligramsKetorolacCelecoxib
Average Inpatient Ondansetron Use1.5 ± 1.91.3 ± 2.2
SecondaryTotal Hospital Stay

Total hospital stay from time fo admission to time of discharge measured in hours

Time frame:
Following surgery
Reported as:
Mean · Hours
Total Hospital Stay
HoursKetorolacCelecoxib
Total Hospital Stay11.6 ± 8.111.9 ± 7.6
SecondaryNumber of Participants With Perioperative Complications

Perioperative Complications measured intraoperatively and postoperatively by type

Time frame:
During and after surgery
Reported as:
Number · Patients
Number of Participants With Perioperative Complications
PatientsKetorolacCelecoxib
Number of Participants With Perioperative Complications56
SecondaryReturn to Activities of Daily Living

Average number of days required for complete return to independent activities of daily living

Time frame:
2 weeks after discharge
Reported as:
Mean · Days
Return to Activities of Daily Living
DaysKetorolacCelecoxib
Return to Activities of Daily Living2.4 ± 0.82.2 ± 0.9
SecondaryDays of Oral Narcotic Use After Discharge

Measured using postoperative questionnaire

Time frame:
2 weeks after discharge
Reported as:
Mean · Days
Days of Oral Narcotic Use After Discharge
DaysKetorolacCelecoxib
Days of Oral Narcotic Use After Discharge5.7 ± 2.83.8 ± 2.6
SecondaryNumber of Oral Narcotic Pills Used After Discharge

Number of oral narcotic pills used after discharge until 2 week postoperative visit.

Time frame:
2 weeks after discharge
Reported as:
Mean · Pills
Number of Oral Narcotic Pills Used After Discharge
PillsKetorolacCelecoxib
Number of Oral Narcotic Pills Used After Discharge8.1 ± 4.06.0 ± 3.6

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketorolac—0/70 (0%)1/70 (1.4%)
Celecoxib—0/68 (0%)2/68 (2.9%)
Most frequent other events
Most frequent other events
EventKetorolacCelecoxib
Intraoperative HemorrhageBlood and lymphatic system disorders0/702/68
Acute Kidney InjuryRenal and urinary disorders1/700/68

Baseline characteristics

Age, Continuous
Age, Continuous(years)KetorolacCelecoxibTotal
Mean56.3 ± 11.355.1 ± 14.455.7 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)KetorolacCelecoxibTotal
Female7068138
Male000
Body Mass Index
Body Mass Index(Kg/m^2)KetorolacCelecoxibTotal
Mean31.8 ± 8.631.7 ± 8.131.7 ± 8.3
Surgical Pathology
Surgical Pathology(Participants)KetorolacCelecoxibTotal
Benign4853101
Malignant221537
Procedure
Procedure(Participants)KetorolacCelecoxibTotal
Robotic Assisted Hysterectomy, +/- BSO, Cysto4853101
Robotic Assisted Hysterectomy, +/- BSO, LND, Cysto221537
Operative Time
Operative Time(Minutes)KetorolacCelecoxibTotal
Mean105 ± 32104 ± 34104 ± 33
Trochar Sites
Trochar Sites(Trochars)KetorolacCelecoxibTotal
Mean4.3 ± 0.54.2 ± 0.44.2 ± 0.5
Preoperative Diagnosis
Preoperative Diagnosis(Participants)KetorolacCelecoxibTotal
Malignancy211536
Premalignancy141529
Leiomyoma8412
Pelvic Pain11819
Abnormal Uterine Bleeding3811
Adnexal Mass101424
Genetic Predisposition to Malignancy347
08

Study locations

1 site
  • Methodist Hospital System
    Memphis, Tennessee 38104, United States
09

References and documents

Publications

  • Azari L, Santoso JT, Osborne SE. Optimal pain management in total abdominal hysterectomy. Obstet Gynecol Surv. 2013 Mar;68(3):215-27. doi: 10.1097/OGX.0b013e31827f5119. PubMed 23945838 ↗
  • Blanton E, Lamvu G, Patanwala I, Barron KI, Witzeman K, Tu FF, As-Sanie S. Non-opioid pain management in benign minimally invasive hysterectomy: A systematic review. Am J Obstet Gynecol. 2017 Jun;216(6):557-567. doi: 10.1016/j.ajog.2016.12.175. Epub 2016 Dec 30. PubMed 28043841 ↗
  • Strom BL, Berlin JA, Kinman JL, Spitz PW, Hennessy S, Feldman H, Kimmel S, Carson JL. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996 Feb 7;275(5):376-82. PubMed 8569017 ↗
  • Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. No abstract available. PubMed 22336956 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Jun 2016, 33 months.

Results were first posted in Jun 2018, 1 year 11 months after primary completion.

Of 90 non-industry phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 33 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2015
First posted
Nov 6, 2017
StartActual
Sep 1, 2013
Primary completionActual
Jun 30, 2016
CompletionActual
Jan 1, 2017
Results first posted
Jun 4, 2018
Last update
Dec 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03331315
Lead sponsor
Michael Ulm, MD
Responsible party
Michael Ulm, MD (Priniciple Investigator, University of Tennessee) — Sponsor-investigator
First posted
Nov 6, 2017
Start date
Sep 1, 2013
Primary completion
Jun 30, 2016
Completion
Jan 1, 2017
Results posted
Jun 4, 2018
Last update
Dec 7, 2023

Study contacts

Michael A Ulm, MD
principal investigator · University of Tennessee

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion